Search Results - "BOURBOULOUX, E"

Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas by Loussouarn, D, Campion, L, Sagan, C, Frenel, J-S, Dravet, F, Classe, J-M, Pioud-Martigny, R, Berton-Rigaud, D, Bourbouloux, E, Mosnier, J-F, Bataille, F-R, Campone, M

“…Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal phenotype (epithelial–mesenchymal…”
Get full text

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours by Campone, M, Levy, V, Bourbouloux, E, Berton Rigaud, D, Bootle, D, Dutreix, C, Zoellner, U, Shand, N, Calvo, F, Raymond, E

“…Everolimus displays antiproliferative effects on cancer cells, yields antiangiogenic activity in established tumours, and shows synergistic activity with…”
Get full text

Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours by Isambert, N, Campone, M, Bourbouloux, E, Drouin, M, Major, A, Yin, W, Loadman, P, Capizzi, R, Grieshaber, C, Fumoleau, P

“…Abstract Purpose C-1311 is a member of the novel imidazoacridinone family of anticancer agents. This phase 1 trial was designed to investigate the safety,…”
Get full text

Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans by Rousseau, C, Bourbouloux, E, Campion, L, Fleury, N, Bridji, B, Chatal, J F, Resche, I, Campone, M

“…It has recently been suggested that FDG accumulation in the brown adipose tissue varies as a function of age, sex and outdoor temperature. The aim of this…”
Get full text

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline taxane-based chemotherapy by CAMPONE, M, CORTES-FUNES, H, ASLANIS, V, FUMOLEAU, P, VOROBIOF, D, MARTIN, M, SLABBER, C. F, CIRUELOS, E, BOURBOULOUX, E, MENDIOLA, C, DELGADO, F. M, COLIN, C

“…To evaluate the single agent activity, pharmacokinetics and tolerability of the novel tubulin targeted agent vinflunine (VFL) (320 mg m(-2) q 21 days) as…”
Get full text

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes by Campone, M., Isambert, N., Bourbouloux, E., Roché, H., Bonneterre, J., Milano, G., Fumoleau, P.

“…Purpose A phase I study was performed to determine the maximal tolerated dose (MTD), recommended dose (RD), safety and efficacy of vinflunine when combined…”
Get full text

3621 POSTER Assessing 2-month Clinical Prognosis in Patients With Solid Tumours – Final Results of PRONOPALL Study by Bourgeois, H, Traore, S, Maillard, P, Marcq, M, Boucher, E, Bourbouloux, E, Baudon, J, Mussault, P, Ingrand, P, Grude, F

Get full text

A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET by Marchand, V, Graveleau, J, Lanctin-Garcia, C, Bourbouloux, E, Bridji, B, Resche, I, Kraeber-Bodéré, F, Rousseau, C

“…Abstract Background. PET/CT may be particularly useful to detect the primary cancer in paraneoplastic cerebellar degeneration (PCD) with anti-Yo which is most…”
Get full text

ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women? by Dubot, C, Bourbouloux, E, Mir, O, Kirscher, S, Rigal, O, Ferrero, J.-M, Curé, H, Blot, E, Allouache, D, Cottu, P, Romieu, G, Lefeuvre, C, Malaurie, E, Tubiana-Mathieu, N, Lacroix-Triki, M, Rollot, F, Peyro-Saint-Paul, H, Orsini, C, Bonnetain, F, Brain, E

Get full text

Adjuvant chemotherapy for luminal breast cancer in elderly women: Feasibility of the ongoing ASTER 70S gerico UNICANCER phase III trial by Bourbouloux, E, Tazi, Y, Cure, H, Ferrero, J.-M, RIgal, O, Romieu, G, Rollot-trad, F, Lacroix-triki, M, Peyro-saint-paul, H, Orsini, C, Bonnetain, F, Brain, E

Get full text

Lapatinib in metastatic breast cancer by Frenel, J-S, Bourbouloux, Berton-Rigaud, Sadot-Lebouvier, Zanetti, Campone

“…Lapatinib is an oral, small-molecule, dual kinase inhibitor that targets both HER2 and the EGF receptor. Lapatinib was approved in June 2008 in Europe for the…”
Get full text

Phase i dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (dl-d2-d3) in patients with refractory solid tumors by CAMPONE, M, ISAMBERT, N, BOURBOULOUX, E, MAURY, S, MONIN-BAROILLE, P, BERILLE, J, FUMOLEAU, P

“…SR271425 is a novel DNA-binding cytotoxic agent with a broad spectrum of antitumor activity in preclinical models,across a variety of the schedule of…”
Get full text

Brown fat in breast cancer patients: analysis of serial 18F-FDG PET/CT scans by Rousseau, C., Bourbouloux, E., Campion, L., Fleury, N., Bridji, B., Chatal, J. F., Resche, I., Campone, M.

“…It has recently been suggested that FDG accumulation in the brown adipose tissue varies as a function of age, sex and outdoor temperature. The aim of this…”
Get full text

Doxorubin-based adjuvant chemotherapy for elderly patients with hormone receptors negative breast carcinoma: a French geriatric oncology group (GERICO) phase II multicentric program by Debled, M, Girre, V, Mertens, C, Blot, E, Rousseau, F, Abadie, S, Uwer, L, Bourbouloux, E, Fourme, E, Gouttenoire, F, Brain, E

Get full text

A personalized adjuvant treatment for women over 70 presenting with a luminal breast cancer? ASTER 70s or an ongoing phase III trial with parallel cohort by the UNICANCER GERICO and UCBG groups for an ongoing question by Brain, E, Romieu, G, Rollot, F, Ferrero, J.M, Curé, H, Rigal, O, Bourbouloux, E, Servent, V, Cottu, P, Baffert, S, Bonnefoi, H, Lacroix-Triki, M, Léger-Falandry, C, Saint-Paul, H. Peyro, Orsini, C, Latouche, A, Bonnetain, F, Girre, V

Get full text

8038 Oxaliplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) in primary or recurrent epithelial ovarian cancer: a pilot study of 31 patients by Frenel, J.S, Classe, J.M, Dravet, F, Leux, C, Rigaud, D. Berton, Bourbouloux, E

Get full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial by Kerbrat, Pierre, Fumoleau, Pierre, Jacquin, Jean-Philippe, Abadie-Lacourtoisie, Sophie, Cany, Laurent, Khayat, David, Paget-Bailly, Sophie, Demarchi, F, N'Guyen, T, Stein, U, Villanueva, C, Guimont, I, Lévy, E, Delbaldo, C, Pouessel, D, Fournel-Fédérico, C, Freyer, G, Tartas, S, Bons, F, Cuvier, C, Hajjaji, N, Capitain, O, Maillart, P, Bonnefoi, H, Durand, M, Madranges, N, Mauriac, L, Durando, X, Durieux, A, Piperno-Neumann, S, Tresca, P, Ferrant, E, Mayer, F, Vanneuville, AC, Servent, V, Guastalla, JP, Biron, P, Dupuy-Brousseau, L, Lancry, L, Trédan, O, Extra, JM, Berton-Rigaud, D, Ferrero, JM, Largillier, R, Gedoin, D, Laguerre, B, Lefeuvre, C, Vauléon, E, Tennevet, I, Mefti-Lacheraf, F, Dalenc, F, André, F, Domont, J, Ezenfis, J, Provençal, J, Bellaiche-Miccio, C, Boutan-Laroze, G, Arsène, O, Merad-Boudia, Z, Orfeuvre, H, Lamy, R, Sarda, C, Salles, B, Cauvin, I, Mangold, M, Bourcier, A, Geay, JF, ElAmarti, R, Combe, M, Dauba, J, Denizon, N, Clavreul, G, Goubely, Y, Delecroix, V, Ligeza-Poisson, V, Leyronnas, C, Teissier, E, Bernard, O, Pottier-Kyndt, V, Drony, S, Moriceau, M, Besson, D, Achille, E, Moran-Ribon, A, Moullet, I, Couderc, B, Burki, F, Schaeffer, F, Montcuquet, P, Baumont, GA, Gréget, S, Ratoanina, JL, Bonichon-Lamichhane, M, Cartron, G, Dupuis, O, Ganem, G, LeRol, A, Antoine, EC, Llory, JF, Loiseau, D

“…In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant…”
Get full text

1680P Feasibility of home-based supervised physical activity (SPA) for metastatic cancer patients receiving oral targeted therapy: The AFSOS-Unicancer QUALIOR randomized phase II study by Lobbedez, F. Joly, Lefeuvre-Plesse, C., Charton, E., Helissey, C., Priou, F., Stefani, L., Simmet, V., Garnier-Tixidre, C., Meneveau, N., Houede, N., Salas, S., Bourbouloux, E., Descotes, J-M., Anota, A., Nenan, S., Rieger, I.

Get full text

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial by Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie-Ange, Tinquaut, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude-Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D'Hondt, Veronique, Lortholary, Alain, Brachet, Pierre-Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, Freyer, Gilles

“…Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an…”
Get more information

125P Cognitive impairment in breast cancer patients up to 18 months after cancer treatments: The French multicentric longitudinal CANTO-Cog cohort substudy by Lobbedez, F. Joly, Hardy-Léger, I., Arbogast, S. Lefevre, Rigal, O., Le Fel, J., Pistilli, B., Petrucci, J., Lévy, C., Capel, A., Coutant, C., Lerebours, F., Vanlemmens, L., Bourbouloux, E., Vaz-Luis, I., Martin, A-L., Everhard, S., André, F., Charles, C., Dauchy, S., Lange, M.

Get full text